Osteochondroma-like parosteal osteosarcoma

Parosteal osteosarcoma is a well-differentiated, predominantly fibro-osseous variant of osteosarcoma, accounting for 5% of all osteosarcomas. We report a case of parosteal osteosarcoma in the metaphyseal area of right femur, of 2 years' duration in a male aged 35 years. It was mistaken for osteochondroma in the initial biopsy, and the possibility of bizarre parosteal osteochondromatous proliferation (BPOP) was also considered. Subsequent excision of the tumor showed it to be a parosteal osteosarcoma. The patient had recurrence of the lesion after 1 year, and he attended a cancer institute. Follow-up showed metastases of the tumor on bone scan.     

Progenitor migration to the thymus and T cell lineage commitment

T cells developing in the thymus are ultimately derived from bone marrow (BM) hematopoietic stem cells (HSCs). An understanding of the developmental steps between HSCs and T cells is important for gaining insight into cancers of the T lineage, improving T cell reconstitution after BM transplantation, and also to help ameliorate immunological defects in aging. In this article, we summarize our current understanding of the inter-related fields of early T cell development and thymic aging, and briefly discuss major unresolved questions in this field.     

Is Inflammatory Bowel Disease an Important Risk Factor Among Older Persons with Colorectal Cancer in the United States? A Population-Based Case–Control Study

Background  

While ulcerative colitis (UC) and Crohn’s disease (CD) are thought to predispose to colorectal cancer (CRC), the association has not been well studied in an older population.     

Diamond Blackfan anemia treatment: past, present, and future

Despite significant improvements in our understanding of the pathophysiology of Diamond Blackfan anemia (DBA), there have been few advances in therapy. The cornerstones of treatment remain corticosteroids, chronic red blood cell transfusions, and hematopoietic stem cell transplantation, each of which is fraught with complications. In this article, we will review the history of therapies that have been offered to patients with DBA, summarize the current standard of care, including management of side effects, and discuss novel therapeutics that are being developed in the context of the research into the roles of ribosomal haplo-insufficiency and p53 activation in Diamond Blackfan anemia.